NASDAQ:BRTX

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

$1.36
-0.09 (-6.19%)
(As of 05/3/2024 ET)
Today's Range
$1.34
$1.43
50-Day Range
$1.23
$1.50
52-Week Range
$1.20
$7.13
Volume
77,372 shs
Average Volume
1.56 million shs
Market Capitalization
$9.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BioRestorative Therapies MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of BioRestorative Therapies in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$165,752 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.96) to ($1.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

BRTX stock logo

About BioRestorative Therapies Stock (NASDAQ:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

BRTX Stock News Headlines

Contrasting BioRestorative Therapies (BRTX) & Its Peers
Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
Analyzing BioRestorative Therapies (BRTX) and Its Rivals
Reviewing BioRestorative Therapies (BRTX) & Its Peers
Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
Contrasting BioRestorative Therapies (BRTX) & Its Rivals
BioRestorative Therapies (BRTX) and Its Peers Financial Survey
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2024
Today
5/04/2024
Next Earnings (Confirmed)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:BRTX
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-14,410,000.00
Net Margins
-9,873.97%
Pretax Margin
-9,886.83%

Debt

Sales & Book Value

Annual Sales
$145,800.00
Book Value
$2.45 per share

Miscellaneous

Free Float
5,308,000
Market Cap
$9.24 million
Optionable
Not Optionable
Beta
62.12
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Lance Alstodt (Age 53)
    Chairman of the Board, President & CEO
    Comp: $954.17k
  • Mr. Robert Eugene Kristal (Age 56)
    Chief Financial Officer
    Comp: $368.12k
  • Mr. Francisco J. Silva (Age 49)
    Chief Scientist, VP of Research & Development, Secretary and Director
    Comp: $891.67k
  • Mr. Robert Paccasassi (Age 55)
    Vice President of Quality Assurance & Regulatory Compliance
    Comp: $233.95k
  • Dr. Wayne J. Olan M.D.
    Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed in 2024?

BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX stock has decreased by 21.5% and is now trading at $1.3650.
View the best growth stocks for 2024 here
.

Are investors shorting BioRestorative Therapies?

BioRestorative Therapies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 40,500 shares, an increase of 103.5% from the March 15th total of 19,900 shares. Based on an average daily trading volume, of 462,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.8% of the shares of the stock are sold short.
View BioRestorative Therapies' Short Interest
.

When is BioRestorative Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BRTX earnings forecast
.

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced its quarterly earnings data on Friday, March, 29th. The company reported ($0.57) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 114.84% and a negative net margin of 9,873.97%.

Who are BioRestorative Therapies' major shareholders?

BioRestorative Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include StoneX Group Inc. (0.51%). Insiders that own company stock include Dale Broadrick, Francisco Silva and Lance Alstodt.
View institutional ownership trends
.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BRTX) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners